Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACAD ACADIA Pharmaceuticals	$21.66 +0.4%	$19.74	$13.40 ▼ $25.23	$3.61B	0.64	1.96 million shs	443,955 shs
MRTX Mirati Therapeutics	$58.70	$58.82	$27.30 ▼ $64.41	$4.12B	0.77	2.76 million shs	N/A
PRGO Perrigo	$27.50 +2.9%	$26.35	$23.14 ▼ $30.93	$3.78B	0.46	1.48 million shs	282,652 shs
RARE Ultragenyx Pharmaceutical	$36.40 +0.1%	$36.61	$29.59 ▼ $60.37	$3.44B	0.25	833,166 shs	245,519 shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACAD ACADIA Pharmaceuticals	-2.49%	-4.05%	-0.14%	+32.17%	+32.74%
MRTX Mirati Therapeutics	0.00%	0.00%	0.00%	0.00%	0.00%
PRGO Perrigo	+0.67%	+1.14%	-0.30%	-3.41%	+4.09%
RARE Ultragenyx Pharmaceutical	-0.44%	-1.28%	+7.35%	+7.45%	-11.53%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACAD ACADIA Pharmaceuticals	4.6716 of 5 stars	4.4	3.0	0.0	0.0	3.2	4.2	2.5
MRTX Mirati Therapeutics	0.4893 of 5 stars	0.0	0.0	0.0	4.7	0.6	0.0	0.6
PRGO Perrigo	4.8334 of 5 stars	2.1	5.0	4.2	3.5	2.7	1.7	2.5
RARE Ultragenyx Pharmaceutical	3.9161 of 5 stars	3.5	1.0	0.0	3.8	2.1	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACAD ACADIA Pharmaceuticals	2.71	Moderate Buy	$27.88	28.72% Upside
MRTX Mirati Therapeutics	0.00	N/A	N/A	N/A
PRGO Perrigo	2.25	Hold	$33.00	20.01% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$87.00	139.01% Upside

Current Analyst Ratings Breakdown

Latest RARE, MRTX, PRGO, and ACAD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ACAD ACADIA Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform ➝ Market Perform	$19.00 ➝ $22.00
6/26/2025	ACAD ACADIA Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$37.00
6/26/2025	ACAD ACADIA Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$30.00
6/26/2025	ACAD ACADIA Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$32.00
6/23/2025	ACAD ACADIA Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$26.00 ➝ $38.00
6/20/2025	RARE Ultragenyx Pharmaceutical	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$64.00
6/6/2025	ACAD ACADIA Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$26.00 ➝ $30.00
6/5/2025	ACAD ACADIA Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
6/5/2025	ACAD ACADIA Pharmaceuticals	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Hold	$18.00 ➝ $23.00
5/28/2025	RARE Ultragenyx Pharmaceutical	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$65.00
5/21/2025	ACAD ACADIA Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$20.00 ➝ $35.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACAD ACADIA Pharmaceuticals	$957.80M	3.78	$0.69 per share	31.38	$4.40 per share	4.92
MRTX Mirati Therapeutics	$12.44M	331.01	N/A	N/A	$17.31 per share	3.39
PRGO Perrigo	$4.37B	0.86	$5.23 per share	5.26	$31.66 per share	0.87
RARE Ultragenyx Pharmaceutical	$560.23M	6.14	N/A	N/A	$2.76 per share	13.19

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACAD ACADIA Pharmaceuticals	$226.45M	$1.37	15.76	28.49	4.77	22.97%	17.46%	10.75%	8/5/2025 (Estimated)
MRTX Mirati Therapeutics	-$740.87M	-$12.22	N/A	N/A	N/A	-1,900.65%	-82.15%	-67.82%	N/A
PRGO Perrigo	-$171.80M	-$1.31	N/A	8.99	N/A	-4.16%	8.93%	3.87%	8/1/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$5.88	N/A	N/A	N/A	-93.04%	-186.49%	-36.81%	7/30/2025 (Estimated)

Latest RARE, MRTX, PRGO, and ACAD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ACAD ACADIA Pharmaceuticals	$0.10	$0.11	+$0.01	$0.11	$239.32 million	$244.32 million
5/7/2025	Q1 2025	PRGO Perrigo	$0.56	$0.60	+$0.04	-$0.05	$1.09 billion	$1.04 billion
5/6/2025	Q1 2025	RARE Ultragenyx Pharmaceutical	-$1.54	-$1.57	-$0.03	-$1.57	$145.98 million	$139.29 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACAD ACADIA Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MRTX Mirati Therapeutics	N/A	N/A	N/A	N/A	N/A
PRGO Perrigo	$1.16	4.22%	N/A	N/A	23 Years
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A

Latest RARE, MRTX, PRGO, and ACAD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/30/2025	PRGO Perrigo	quarterly	$0.29	4.55%	5/30/2025	5/30/2025	6/17/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACAD ACADIA Pharmaceuticals	N/A	2.88	2.80
MRTX Mirati Therapeutics	N/A	7.54	7.40
PRGO Perrigo	0.82	2.36	1.28
RARE Ultragenyx Pharmaceutical	N/A	2.40	2.24

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACAD ACADIA Pharmaceuticals	96.71%
MRTX Mirati Therapeutics	N/A
PRGO Perrigo	95.91%
RARE Ultragenyx Pharmaceutical	97.67%

Insider Ownership

Company	Insider Ownership
ACAD ACADIA Pharmaceuticals	28.30%
MRTX Mirati Therapeutics	3.26%
PRGO Perrigo	0.40%
RARE Ultragenyx Pharmaceutical	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACAD ACADIA Pharmaceuticals	510	167.36 million	120.00 million	Optionable
MRTX Mirati Therapeutics	587	70.15 million	67.86 million	Optionable
PRGO Perrigo	8,379	137.48 million	136.93 million	Optionable
RARE Ultragenyx Pharmaceutical	1,294	94.54 million	89.34 million	Optionable

RARE, MRTX, PRGO, and ACAD Headlines

Recent News About These Companies

Ultragenyx Pharmaceutical (NASDAQ:RARE) Shares Cross Below 50 Day Moving Average - What's Next?

July 1 at 4:19 AM | marketbeat.com

RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome

June 30 at 12:41 PM | zacks.com

Ultragenyx stock rises after FDA grants breakthrough therapy status for Angelman syndrome drug

June 27, 2025 | au.investing.com

Ultragenyx Gets FDA Designation to Expedite GTX-102 Drug Development

June 27, 2025 | marketwatch.com

Ultragenyx Pharmaceutical Inc. Receives FDA Breakthrough Therapy Designation for GTX-102 to Treat Angelman Syndrome

June 27, 2025 | quiverquant.comQ

Ultragenyx Receives Breakthrough Therapy Designation for GTX-102 in Angelman Syndrome

June 27, 2025 | globenewswire.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) D. Sanders Sells 2,405 Shares

June 24, 2025 | insidertrades.com

FDA Conditional Pathway Not Necessary, Rare Disease Experts Say, While Applauding Intent

June 23, 2025 | biospace.comB

Insider Selling: Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Sells 2,405 Shares of Stock

June 23, 2025 | marketbeat.com

Guggenheim Reiterates "Buy" Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

June 22, 2025 | americanbankingnews.com

Ultragenyx Pharmaceutical Inc. Grants 48,731 Restricted Stock Units to Newly Hired Non-Executive Officers

June 20, 2025 | quiverquant.comQ

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

June 20, 2025 | globenewswire.com

Guggenheim Reaffirms Buy Rating for Ultragenyx Pharmaceutical (NASDAQ:RARE)

June 20, 2025 | marketbeat.com

GAMMA Investing LLC Acquires 26,625 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 17, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Bought by Assenagon Asset Management S.A.

June 15, 2025 | marketbeat.com

Wealth Enhancement Advisory Services LLC Sells 14,701 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 15, 2025 | marketbeat.com

Ultragenyx Pharmaceutical (NASDAQ:RARE) Stock Price Up 3.5% - What's Next?

June 12, 2025 | marketbeat.com

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Shares Purchased by SG Americas Securities LLC

June 12, 2025 | marketbeat.com

Wedge Capital Management L L P NC Buys Shares of 35,695 Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

June 11, 2025 | marketbeat.com

Research Analysts Offer Predictions for RARE FY2026 Earnings

June 10, 2025 | marketbeat.com

China's rare earth exports climb 23% in May ahead of trade talks with the U.S.

June 9, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Stocks Getting Rare Double Upgrades From Analysts
By Chris Markoch | June 6, 2025
View 3 Stocks Getting Rare Double Upgrades From Analysts
These 3 Dividend Stocks Combine Strong Yields With Upside
By Chris Markoch | June 20, 2025
View These 3 Dividend Stocks Combine Strong Yields With Upside
Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
By Sam Quirke | June 30, 2025
View Tesla’s Robotaxi Hype Fuels Bullish Price Targets to $500
Why Qualcomm’s Latest Price Target Can't Be Ignored
By Sam Quirke | June 24, 2025
View Why Qualcomm’s Latest Price Target Can't Be Ignored
Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal
By Sam Quirke | June 11, 2025
View Tesla Stock: Why These 2 Downgrades Are Actually a Buy Signal

RARE, MRTX, PRGO, and ACAD Company Descriptions

ACADIA Pharmaceuticals NASDAQ:ACAD

$21.66 +0.09 (+0.40%)

As of 12:50 PM Eastern

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer's disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Mirati Therapeutics NASDAQ:MRTX

Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.

Perrigo NYSE:PRGO

$27.50 +0.78 (+2.91%)

As of 12:50 PM Eastern

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers. It also offers healthy lifestyle products, such as smoking cessation, well-being, and weight management products; skin care products consisting of dermatological care, scar management, lice treatment, and other products for various skin conditions; women's health products comprising feminine hygiene and contraceptives; vitamins, minerals, and supplements; rare diseases business; and other miscellaneous self-care products. The company sells its products under the Compeed, Dr. Fresh, Firefly, Good Sense, Good Start, Mederma, Nasonex, Plackers, Prevacid24HR, REACH, Rembrandt, Steripod, Opill, Solpadeine, Coldrex, Physiomer, NiQuitin, ACO, ellaOne, Compeed Stops, XLS, Arterin, Davitamon, Apiserum, Abtei, and Nicorette brands. It also offers contract manufacturing services. The company sells its products through retail drug, supermarket, and mass merchandise chains; e-commerce stores; wholesalers; pharmacies; drug and grocery retailers; and para-pharmacies. The company was formerly known as Perrigo Company and changed its name to Perrigo Company plc in December 2013. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.

Ultragenyx Pharmaceutical NASDAQ:RARE

$36.40 +0.04 (+0.11%)

As of 12:50 PM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time